Sabrina Rosaria Paparo, Silvia Martina Ferrari, Armando Patrizio, Giusy Elia, Francesca Ragusa, Chiara Botrini, Eugenia Balestri, Fabrizio Guarneri, Salvatore Benvenga, Alessandro Antonelli, Poupak Fallahi
Journal: Frontiers in endocrinology 2022;13():930756
PMID: 35837308
Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. Myo is mainly derived from dietary intake while its endogenous production is generated from glucose by enzymatic reactions. Moreover, Myo is also synthesized by catabolism of phosphatidylinositol (PI), phosphoinositides (PIP), and inositol phosphates (IP). Myo has a determinant role in thyroid function and autoimmune diseases as it regulates iodine organification and thyroid hormone biosynthesis by the formation of hydrogen peroxide (HO) in thyrocytes. Depletion of Myo that is involved in the thyroid stimulating hormone (TSH) signaling pathway, may cause the development of thyroid diseases such as hypothyroidism. TSH levels significantly decreased in patients with subclinical hypothyroidism, with or without autoimmune thyroiditis, after treatment with Myo plus Selenium (Myo+Se). In addition to TSH, antithyroid autoantibodies are reduced. This review summarizes the role of Myo in the thyroidal physiology and its role in the management of some thyroid diseases.
Copyright © 2022 Paparo, Ferrari, Patrizio, Elia, Ragusa, Botrini, Balestri, Guarneri, Benvenga, Antonelli and Fallahi.
Full Text Sources:
Medical:
Miscellaneous:
Research Materials:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.